Top

Clinical Reviews in Allergy & Immunology

Published in:

01-04-2018

The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review

Authors: Mingjie Yao, Leijie Wang, Patrick S. C. Leung, Yanmei Li, Shuhong Liu, Lu Wang, Xiaodong Guo, Guangde Zhou, Ying Yan, Guiwen Guan, Xiangmei Chen, Christopher L. Bowlus, Tianhui Liu, Jidong Jia, M. Eric Gershwin, Xiong Ma, Jingmin Zhao, Fengmin Lu

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2018

Abstract

There is significant void in establishing validated non-invasive surrogate biomarkers of liver fibrosis/cirrhosis in chronic liver diseases (CLD). Golgi protein 73 (GP73) has been suggested as a potential serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, significant background of cirrhosis could have accounted for the elevation of serum GP73 in HCC. In this study, we have taken advantage of a well-defined extensive cohort of 3044 patients with either compensated cirrhosis (n = 1247), decompensated cirrhosis (n = 841) or pre-cirrhotic CLD (n = 956) and our ability to quantify serum GP73 to define the potential of serum GP73 as a biomarker of liver cirrhosis/fibrosis in CLD. The diagnostic value of GP73 was compared with aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis index based on four factors (FIB-4) and liver stiffness measurement (LSM). Immunohistochemical analysis was performed to measure hepatic GP73 expression. Receiver operating characteristic curve analysis demonstrated that serum GP73 had a good diagnostic potential for compensated cirrhosis regardless of etiology. The diagnostic performance of GP73 is better than APRI, FIB-4 and similar with LSM, especially in patients with severe inflammation, steatosis and cholestasis. Notably, in patients of autoimmune liver diseases, non-alcoholic fatty liver disease and viral hepatitis, serum GP73 also exhibited diagnostic value for advanced fibrosis as well as cirrhosis. Furthermore, there is also a gradual increase in GP73 expression with disease progression from mild fibrosis to cirrhosis. In conclusion, GP73 is an effective and reliable serological marker for the diagnosis of advanced fibrosis and prediction of appearance of cirrhosis.

Available only for authorised users

Ganem D, Prince AM (2004) Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 350(11):1118–1129. https://doi.org/10.1056/NEJMra031087 CrossRefPubMed

Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45(2):507–539. https://doi.org/10.1002/hep.21513 CrossRefPubMed

Thein HH, Yi Q, Dore GJ, Krahn MD (2008) Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48(2):418–431. https://doi.org/10.1002/hep.22375 CrossRefPubMed

Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7(8):448–458. https://doi.org/10.1038/nrgastro.2010.100 CrossRefPubMedPubMedCentral

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6):2005–2023. https://doi.org/10.1002/hep.25762 CrossRefPubMed

Fan JG, Farrell GC (2009) Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50(1):204–210. https://doi.org/10.1016/j.jhep.2008.10.010 CrossRefPubMed

Kaswala DH, Lai M, Afdhal NH (2016) Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016. Dig Dis Sci 61(5):1356–1364. https://doi.org/10.1007/s10620-016-4079-4 CrossRefPubMed

Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, Guo C, Wei Y, Tang R, Miao Q, Zhang J, Li Y, Fang J, Qiu D, Krawitt EL, Bowlus CL, Gershwin ME, Wang Q, Ma X (2017) The management of autoimmune hepatitis patients with decompensated cirrhosis: real-world experience and a comprehensive review. Clin Rev Allergy Immunol 52(3):424–435. https://doi.org/10.1007/s12016-016-8583-2 CrossRefPubMed

Yang F, Wang Q, Wang Z, Miao Q, Xiao X, Tang R, Chen X, Bian Z, Zhang H, Yang Y, Sheng L, Fang J, Qiu D, Krawitt EL, Gershwin ME, Ma X (2016) The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol 50(1):114–123. https://doi.org/10.1007/s12016-015-8516-5 CrossRefPubMed

10.

Neuberger J (2016) An update on liver transplantation: a critical review. J Autoimmun 66:51–59. https://doi.org/10.1016/j.jaut.2015.08.021 CrossRefPubMed

11.

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5):1547–1554. https://doi.org/10.1002/hep.27368 CrossRefPubMed

12.

Chang TT, Liaw YF, SS W, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52(3):886–893. https://doi.org/10.1002/hep.23785 CrossRefPubMed

13.

Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M (2000) Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132(7):517–524. https://doi.org/10.7326/0003-4819-132-7-200004040-00002 CrossRefPubMed

14.

Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521–1531. https://doi.org/10.1056/NEJMoa033364 CrossRefPubMed

15.

Kerkar N, Yanni G (2016) ‘De novo’ and ‘recurrent’ autoimmune hepatitis after liver transplantation: a comprehensive review. J Autoimmun 66:17–24. https://doi.org/10.1016/j.jaut.2015.08.017 CrossRefPubMed

16.

European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado (2015) EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63(1):237–264. https://doi.org/10.1016/j.jhep.2015.04.006 CrossRef

17.

European Association for the Study of the Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57(1):167–185. https://doi.org/10.1016/j.jhep.2012.02.010 CrossRef

18.

European Association for the Study of the Liver. Electronic address eee, European Association for the Study of D, European Association for the Study of O (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004 CrossRef

19.

Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97(10):2614–2618. https://doi.org/10.1111/j.1572-0241.2002.06038.x CrossRefPubMed

20.

Bedossa P, Dargere D, Paradis V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38(6):1449–1457. https://doi.org/10.1016/j.hep.2003.09.022 CrossRefPubMed

21.

Brunetti E, Silini E, Pistorio A, Cavallero A, Marangio A, Bruno R, Filice C (2004) Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis. J Hepatol 40(3):501–506. https://doi.org/10.1016/j.jhep.2003.11.008 CrossRefPubMed

22.

Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, Cales P (2005) Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 41(2):257–264. https://doi.org/10.1002/hep.20535 CrossRefPubMed

23.

Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J Med 344(7):495–500. https://doi.org/10.1056/nejm200102153440706 CrossRefPubMed

24.

Tozzoli R, Villalta D, Bizzaro N (2016) Challenges in the standardization of autoantibody testing: a comprehensive review. Clin Rev Allergy Immunol 53(1):68–77. https://doi.org/10.1007/s12016-016-8579-y CrossRef

25.

Lieber CS, Weiss DG, Morgan TR, Paronetto F (2006) Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 101(7):1500–1508. https://doi.org/10.1111/j.1572-0241.2006.00610.x CrossRefPubMed

26.

Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, Moscarella S, Boddi V, Petrarca A, Laffi G, Marra F, Pinzani M (2008) Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 47(2):380–384. https://doi.org/10.1002/hep.22007 CrossRefPubMed

27.

Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR (2007) Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 14(5):360–369. https://doi.org/10.1111/j.1365-2893.2006.00811.x CrossRefPubMed

28.

Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, Fruhwirth R, Marcellini M, Pinzani M (2008) Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 48(2):442–448. https://doi.org/10.1002/hep.22376 CrossRefPubMed

29.

Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Buchler MW, Seitz HK, Mueller S (2008) Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 48(5):1718–1723. https://doi.org/10.1002/hep.22577 CrossRefPubMed

30.

Trivedi PJ, Bruns T, Cheung A, Li KK, Kittler C, Kumagi T, Shah H, Corbett C, Al-Harthy N, Acarsu U, Coltescu C, Tripathi D, Stallmach A, Neuberger J, Janssen HL, Hirschfield GM (2014) Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol 60(6):1249–1258. https://doi.org/10.1016/j.jhep.2014.01.029 CrossRefPubMed

31.

Munro S (1998) Localization of proteins to the Golgi apparatus. Trends Cell Biol 8(1):11–15. https://doi.org/10.1016/S0962-8924(97)01197-5 CrossRefPubMedPubMedCentral

32.

Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, Yang Z, Cai J, Li H, Chen J, Zhong S, Mohanti SR, Lopez-Soler R, Millis JM, Huang J, Zhang H (2010) Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 59(12):1687–1693. https://doi.org/10.1136/gut.2010.214916 CrossRefPubMed

33.

Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D’Amelio A, Lok AS, Block TM (2005) GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 43(6):1007–1012. https://doi.org/10.1016/j.jhep.2005.05.028 CrossRefPubMed

34.

Hu JS, Wu DW, Liang S, Miao XY (2010) GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol 27(2):339–345. https://doi.org/10.1007/s12032-009-9215-y CrossRefPubMed

35.

Li X, Wu K, Fan D (2009) Serum Golgi phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma. Hepatology 50(1):325. https://doi.org/10.1002/hep.23028 CrossRefPubMed

36.

Wang Y, Yang H, Xu H, Lu X, Sang X, Zhong S, Huang J, Mao Y (2014) Golgi protein 73, not glypican-3, may be a tumor marker complementary to alpha-fetoprotein for hepatocellular carcinoma diagnosis. J Gastroenterol Hepatol 29(3):597–602. https://doi.org/10.1111/jgh.12461 CrossRefPubMed

37.

Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, Block TM, Mehta AS (2009) Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomark Prev 18(6):1914–1921. https://doi.org/10.1158/1055-9965.epi-08-0980 CrossRef

38.

Hou SC, Xiao MB, Ni RZ, Ni WK, Jiang F, Li XY, Lu CH, Chen BY (2013) Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma. Oncol Lett 6(4):1152–1158. https://doi.org/10.3892/ol.2013.1522 CrossRefPubMedPubMedCentral

39.

Morota K, Nakagawa M, Sekiya R, Hemken PM, Sokoll LJ, Elliott D, Chan DW, Dowell BL (2011) A comparative evaluation of Golgi protein-73, fucosylated hemopexin, alpha-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med 49(4):711–718. https://doi.org/10.1515/CCLM.2011.097 CrossRefPubMed

40.

Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M (2006) The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43(6):1303–1310. https://doi.org/10.1002/hep.21176 CrossRefPubMed

41.

Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP (2007) Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 5(8):938–945, 945.e931–934. https://doi.org/10.1016/j.cgh.2007.02.039 CrossRefPubMed

42.

Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136(1):138–148. https://doi.org/10.1053/j.gastro.2008.09.014 CrossRefPubMed

43.

Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, American Association for the Study of Liver D (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63(1):261–283. https://doi.org/10.1002/hep.28156 CrossRefPubMed

44.

AASLD/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62(3):932–954. https://doi.org/10.1002/hep.27950 CrossRef

45.

Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW, International Autoimmune Hepatitis G (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48(1):169–176. https://doi.org/10.1002/hep.22322 CrossRefPubMed

46.

Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, American Association for Study of Liver D (2009) Primary biliary cirrhosis. Hepatology 50(1):291–308. https://doi.org/10.1002/hep.22906 CrossRefPubMed

47.

Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24(2):289–293. https://doi.org/10.1002/hep.510240201 CrossRefPubMed

48.

Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94(9):2467–2474. https://doi.org/10.1111/j.1572-0241.1999.01377.x CrossRefPubMed

49.

Castera L, Forns X, Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48(5):835–847. https://doi.org/10.1016/j.jhep.2008.02.008 CrossRefPubMed

50.

Gong Y, Long Q, Xie H, Zhang T, Peng T (2012) Cloning and characterization of human Golgi phosphoprotein 2 gene (GOLPH2/GP73/GOLM1) promoter. Biochem Biophys Res Commun 421(4):713–720. https://doi.org/10.1016/j.bbrc.2012.04.067 CrossRefPubMed

51.

Schmetterer KG, Neunkirchner A, Wojta-Stremayr D, Leitner J, Steinberger P, Pickl WF (2015) STAT3 governs hyporesponsiveness and granzyme B-dependent suppressive capacity in human CD4+ T cells. FASEB J 29(3):759–771. https://doi.org/10.1096/fj.14-257584 CrossRefPubMed

52.

Bachert C, Fimmel C, Linstedt AD (2007) Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic 8(10):1415–1423. https://doi.org/10.1111/j.1600-0854.2007.00621.x CrossRefPubMed

53.

Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, Fimmel CJ (2000) GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 249(1–2):53–65. https://doi.org/10.1016/S0378-1119(00)00136-0 CrossRefPubMedPubMedCentral

54.

Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N (2010) AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 45(12):1272–1282. https://doi.org/10.1007/s00535-010-0278-5 CrossRefPubMed

55.

Shi Y, Chen J, Li L, Sun Z, Zen L, Xu S, Zhang Y, Zhang L (2011) A study of diagnostic value of Golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat 10(3):287–294. https://doi.org/10.7785/tcrt.2012.500205 CrossRefPubMed

56.

Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Graff A, Gusmirovic I, Solomon H, Luxon BA, Bacon BR, Fimmel CJ (2004) Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol 99(6):1087–1095. https://doi.org/10.1111/j.1572-0241.2004.30572.x CrossRefPubMed

57.

Chen X, Wang Y, Tao J, Shi Y, Gai X, Huang F, Ma Q, Zhou Z, Chen H, Zhang H, Liu Z, Sun Q, Peng H, Chen R, Jing Y, Yang H, Mao Y, Zhang H (2015) mTORC1 up-regulates GP73 to promote proliferation and migration of hepatocellular carcinoma cells and growth of xenograft tumors in mice. Gastroenterology 149(3):741–752 e714. https://doi.org/10.1053/j.gastro.2015.05.005 CrossRefPubMed

58.

Liu Y, Zhang X, Sun T, Jiang J, Li Y, Chen M, Wei Z, Jiang W, Zhou L (2016) Knockdown of Golgi phosphoprotein 2 inhibits hepatocellular carcinoma cell proliferation and motility. Oncotarget 7(16):21404–21415. 10.18632/oncotarget.7271 PubMedPubMedCentralCrossRef

59.

Wei H, Li B, Zhang R, Hao X, Huang Y, Qiao Y, Hou J, Li X, Li X (2013) Serum GP73, a marker for evaluating progression in patients with chronic HBV infections. PLoS One 8(2):e53862. https://doi.org/10.1371/journal.pone.0053862 CrossRefPubMedPubMedCentral

60.

Zhang YL, Zhang YC, Han W, Li YM, Wang GN, Yuan S, Wei FX, Wang JF, Jiang JJ, Zhang YW (2014) Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer. World J Gastroenterol 20(32):11287–11296. https://doi.org/10.3748/wjg.v20.i32.11287 CrossRefPubMedPubMedCentral

61.

Zhao J, Xu T, Wang F, Cai W, Chen L (2017) miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73. Biomed Pharmacother 90:744–751. https://doi.org/10.1016/j.biopha.2017.04.029 CrossRefPubMed

62.

Liu T, Yao M, Liu S, Wang L, Wang L, Hou J, Ma X, Jia J, Zhao J, Zhuang H, Lu F (2017) Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget 8(10):16498–16506. https://doi.org/10.18632/oncotarget.14954

63.

Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, Schmidt MA, Lu M (2014) The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat 21(12):930–937. https://doi.org/10.1111/jvh.12224 CrossRefPubMed

64.

Xiao G, Yang J, Yan L (2015) Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 61(1):292–302. https://doi.org/10.1002/hep.27382 CrossRefPubMed

65.

Qiao Y, Chen J, Li X, Wei H, Xiao F, Chang L, Zhang R, Hao X, Wei H (2014) Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin Biochem 47(16–17):216–222. https://doi.org/10.1016/j.clinbiochem.2014.08.010 CrossRefPubMed

66.

Fraquelli M, Rigamonti C, Casazza G, Donato MF, Ronchi G, Conte D, Rumi M, Lampertico P, Colombo M (2011) Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol 54(4):621–628. https://doi.org/10.1016/j.jhep.2010.07.017 CrossRefPubMed

67.

Czaja AJ (1984) Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis 4(1):1–12. https://doi.org/10.1055/s-2008-1040641 CrossRefPubMed

68.

Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D (2016) Cutting edge issues in autoimmune hepatitis. J Autoimmun 75:6–19. https://doi.org/10.1016/j.jaut.2016.07.005 CrossRefPubMed

69.

Ma WT, Chang C, Gershwin ME, Lian ZX (2017) Development of autoantibodies precedes clinical manifestations of autoimmune diseases: a comprehensive review. J Autoimmun 83:95–112. https://doi.org/10.1016/j.jaut.2017.07.003 CrossRefPubMed

70.

Ye Q-H, Zhu W-W, Zhang J-B, Qin Y, Lu M, Lin G-L, Guo L, Zhang B, Lin Z-H, Roessler S, Forgues M, Jia H-L, Lu L, Zhang X-F, Lian B-F, Xie L, Dong Q-Z, Tang Z-Y, Wang XW, Qin L-X (2016) GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis. Cancer Cell 30(3):444–458. https://doi.org/10.1016/j.ccell.2016.07.017 CrossRefPubMedPubMedCentral

71.

Geier A, Jahn D, Hermanns H (2017) Interleukin-6—the dark side of liver regeneration in chronic liver disease. Hepatology 66(2):667–668. https://doi.org/10.1002/hep.29136 CrossRefPubMed

72.

Lanton T, Shriki A, Nechemia-Arbely Y, Abramovitch R, Levkovitch O, Adar R, Rosenberg N, Paldor M, Goldenberg D, Sonnenblick A, Peled A, Rose-John S, Galun E, Axelrod JH (2017) Interleukin 6-dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis. Hepatology 65(5):1600–1611. https://doi.org/10.1002/hep.29004 CrossRefPubMed

73.

Tachibana S, Zhang X, Ito K, Ota Y, Cameron AM, Williams GM, Sun Z (2014) Interleukin-6 is required for cell cycle arrest and activation of DNA repair enzymes after partial hepatectomy in mice. Cell Biosci 4(1):6. https://doi.org/10.1186/2045-3701-4-6 CrossRefPubMedPubMedCentral

74.

Xu MJ, Feng D, Wu H, Wang H, Chan Y, Kolls J, Borregaard N, Porse B, Berger T, Mak TW, Cowland JB, Kong X, Gao B (2015) Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology 61(2):692–702. https://doi.org/10.1002/hep.27447 CrossRefPubMed

75.

Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J, Mehta AS, Marrero J, Gish R, Norton PA (2012) Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark 11(4):161–171. https://doi.org/10.3233/CBM-2012-00276 CrossRefPubMedPubMedCentral

76.

Taher TE, Bystrom J, Ong VH, Isenberg DA, Renaudineau Y, Abraham DJ, Mageed RA (2017) Intracellular B lymphocyte signalling and the regulation of humoral immunity and autoimmunity. Clin Rev Allergy Immunol 53(2):237–264. https://doi.org/10.1007/s12016-017-8609-4 CrossRefPubMedPubMedCentral

77.

Fujimura T, Fujimoto T, Itaya-Hironaka A, Miyaoka T, Yoshimoto K, Sakuramoto-Tsuchida S, Yamauchi A, Takeda M, Tsujinaka H, Tanaka Y, Takasawa S (2017) Significance of interleukin-6/STAT pathway for the gene expression of REG Ialpha, a new autoantigen in Sjogren’s syndrome patients, in salivary duct epithelial cells. Clin Rev Allergy Immunol 52(3):351–363. https://doi.org/10.1007/s12016-016-8570-7 CrossRefPubMed

Title: The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review
Authors: Mingjie Yao
Leijie Wang
Patrick S. C. Leung
Yanmei Li
Shuhong Liu
Lu Wang
Xiaodong Guo
Guangde Zhou
Ying Yan
Guiwen Guan
Xiangmei Chen
Christopher L. Bowlus
Tianhui Liu
Jidong Jia
M. Eric Gershwin
Xiong Ma
Jingmin Zhao
Fengmin Lu
Publication date: 01-04-2018
Publisher: Springer US
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2018
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-017-8655-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

The Immunologic Paradoxes of IgG4-Related Disease

Unmet Needs in the Pathogenesis and Treatment of Vasculitides

Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies

Chitin and Its Effects on Inflammatory and Immune Responses

Review: Diagnosing Common Variable Immunodeficiency Disorder in the Era of Genome Sequencing

The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis—a Meta-Analysis Update of 14 Randomized Controlled Trials

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page